Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Create alerts with multiple filters including highs/low, comparative values, and turning points. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Dare Bioscience Inc (DARE)

Dare Bioscience Inc (DARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 104,195
  • Shares Outstanding, K 84,711
  • Annual Sales, $ 0 K
  • Annual Income, $ -38,700 K
  • 60-Month Beta 1.28
  • Price/Sales 9.41
  • Price/Cash Flow N/A
  • Price/Book 3.32
Trade DARE with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.14
  • Number of Estimates 2
  • High Estimate -0.12
  • Low Estimate -0.17
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0500 +12.38%
on 07/27/22
1.2900 -8.53%
on 08/09/22
-0.0500 (-4.07%)
since 07/11/22
3-Month
0.9201 +28.25%
on 05/12/22
1.4650 -19.45%
on 06/24/22
+0.2399 (+25.52%)
since 05/11/22
52-Week
0.9201 +28.25%
on 05/12/22
2.5100 -52.99%
on 12/08/21
-0.5200 (-30.59%)
since 08/11/21

Most Recent Stories

More News
Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update

June 30, 2022: $32.1 million in cash and cash equivalentsJuly 2022: approximately $18.0 million in cash received subsequent to quarter-end: $10.0 million...

DARE : 1.1800 (-4.07%)
Daré Bioscience to Host Second Quarter 2022 Financial Results and Company Update Conference Call and Webcast on August 9, 2022

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will...

DARE : 1.1800 (-4.07%)
Daré Bioscience to Participate in Maxim Group Women’s Health Panel

SAN DIEGO, July 07, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina...

DARE : 1.1800 (-4.07%)
Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis

Daré will receive a $10 million upfront payment from Organon An estimated 21 million American women experience bacterial vaginosis SAN DIEGO, June 30,...

DARE : 1.1800 (-4.07%)
Daré Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022

Meeting to be reconvened solely with respect to Proposal 5...

DARE : 1.1800 (-4.07%)
Daré Bioscience to Participate in H.C. Wainwright Global Investment Conference

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina...

DARE : 1.1800 (-4.07%)
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 28.57% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

DARE : 1.1800 (-4.07%)
KALA : 0.3280 (-5.75%)
Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update

$39.3 million in cash and cash equivalents at March 31, 2022Announced initiation of DARE-HRT1 Phase 1/2 clinical study in April 2022Organon exclusive...

DARE : 1.1800 (-4.07%)
Daré Bioscience Announces NIH Grant Award

Supports research to define end-user preferences among U.S. women to informthe design of long-acting injectable hormonal contraception Daré is developing...

DARE : 1.1800 (-4.07%)
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 14.29% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

DARE : 1.1800 (-4.07%)
KLDO : 0.0022 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Dare Bioscience, Inc. is a healthcare company. It involved in the development and commercialization of products in women's reproductive health. Dare Bioscience, Inc., formerly known as Cerulean Pharma Inc., is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 1.2873
2nd Resistance Point 1.2659
1st Resistance Point 1.2229
Last Price 1.1800
1st Support Level 1.1585
2nd Support Level 1.1371
3rd Support Level 1.0941

See More

52-Week High 2.5100
Fibonacci 61.8% 1.9027
Fibonacci 50% 1.7150
Fibonacci 38.2% 1.5274
Last Price 1.1800
52-Week Low 0.9201

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar